Современные тенденции в гинекологической онкологии

Абстрактный

Cell-free DNA methylation patterns for early detection and management of ovarian and breast cancers - Martin Widschwendter, University College London

Martin Widschwendter

Abstract: Despite a myriad of attempts in the last three decades to diagnose ovarian cancer (OC) and breast cancer (BC) earlier, this clinical aim remains a significant challenge. Aberrant methylation patterns of linked CpGs analyzed in DNA fragments shed by cancers into the bloodstream (i.e. cell-free DNA) can provide highly specific signals indicating cancer presence. We analyzed cancerous and non-cancerous tissues using a methylation array or reduced representation bisulfite sequencing to discover the most specific OC and BC methylation patterns. A DNA-methylation-serum-marker panel was developed using targeted ultra-high coverage bisulfite sequencing in 151 women and validated in 250 women with various conditions, particularly those associated with high CA125 levels (endometriosis and other benign pelvic masses), serial samples from 25 patients undergoing neoadjuvant chemotherapy and a nested case control study of 172 UKCTOCS control arm participants which included serum samples up to two years prior to OC diagnosis. In addition, we analyzed 419 BC patients (in both pre- and post-adjuvant chemotherapy samples) from SUCCESS (Simultaneous Study of Gemcitabine- Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial) and 925 women (pre-diagnosis) from the UKCTOCS (UK Collaborative Trial of Ovarian Cancer Screening) population cohort, with overall survival and occurrence of incident BC (that may or may not lead to death), respectively, as primary endpoints. The cell-free DNA amount and average fragment size in the serum samples was up to 10 times higher than average published values (based on samples that were immediately processed) due to leakage of DNA from white blood cells as a result of the delay in time with respect to serum separation. For BC, one specific marker was an independent poor prognostic marker in pre-diagnosed with a fatal BC within 3-6 and 6-12 months of sample donation, respectively, with a specificity of 88%. The sensitivity with respect to detecting fatal BC was ~4-fold higher when compared to non-fatal BC.Our data suggests that DNA methylation (DNAme) patterns in cell free DNA have the potential to detect a proportion of OCs and BCs up to two years in advance of diagnosis and may potentially guide personalized treatment. The prospective use of novel collection vials which stabilize blood cells and reduce background DNA contamination in serum/plasma samples will facilitate clinical implementation of liquid biopsy analyses.

Introduction: With in excess of 22,000 new cases every year for 14,000 passings in the United States, ovarian malignant growth (OvC) is the fifth reason for death by disease for female patients. In spite of changes in suggestions and medicines in the course of recent decades, the visualization has been just somewhat changed, with endurance paces of under 30% for cutting edge stages. Improved information on tumor science, got specifically from universal activities, for example, The Cancer Genome Atlas and the Ovarian Cancer Association Consortium, has not brought any advantage for the greater part of the patients. Just those with homologous recombination insufficiency, remarkably BRCA1 or BRCA2 changes, have seen sensational endurance upgrades in the most recent years. It is, without a doubt, hard to comprehend the atomic intricacy of OvC in an individual patient. Genomic examines distributed to date have been founded on tumor tissue examinations that must be deciphered with alert because of the spatial heterogeneity of these tumors. These investigations depend on tissue tests, which require obtrusive techniques (medical procedure, radio-guided biopsies) that can be related with confusions for about 5% of patients, can't be rehashed at a few time focuses. Additionally, CA125 and HE4, the two routinely-utilized serum markers, have low affectability and explicitness for beginning period sicknesses, forestalling their utilization for screening and analysis [11]. The advancement of dependable biomarkers recognized by non-intrusive methodology is along these lines a flat out need. This procedure will take into consideration better evaluation and checking of patients rewarded for OvC, just as the chance of investigating better approaches to comprehend OvC multifaceted nature from beginning times to late backslide. Lately, trust has originated from circling tumor markers (otherwise called "fluid biopsies"), including coursing tumor DNA (ctDNA), flowing tumor cells (CTC), flowing miRNA, and circling exosomes. We portray here the enthusiasm of fluid biopsies in screening and early analysis, anticipation, forecast of treatment reaction, location of negligible leftover illness, and early conclusion of backslide for ovarian carcinoma. We have led a quest for distributed articles alluding to these inquiries. The current writing assessing fluid biopsies with regards to OvC has been evaluated.

Methods: The audit was finished after the PRISMA (Preferred Reporting Items for Systematic surveys and Meta-Analyses) guidelines.The research was directed in PubMed (https://www.ncbi.nlm.nih.gov/pubmed), utilizing the accompanying MESH words: "sans cell tumor DNA" or "flowing tumor DNA", "coursing tumor cells", "circling microRNA" or "without cell microRNA" or "serum miRNA", "circling extracellular vesicles" or "coursing exosomes" and "ovarian neoplasm". All articles in English recorded from 2000 to 28 February 2019 were qualified. Articles were chosen autonomously by two writers, RM and RS. We previously chose papers of enthusiasm as indicated by the article's title. A further determination was then done dependent on unique investigation. After complete composition perusing of the chose articles, we dispensed with all papers outside the field of this survey, i.e., those not concentrated on fluid biopsies or ovarian carcinomas. All staying unique articles, and a few surveys, were remembered for this audit.

Result: Coursing Cell-Free DNA and Circulating Tumor DNA The nearness of sans cell DNA (cfDNA) flowing in natural liquids is a physiological marvel, optional to DNA discharge, for the most part by apoptotic or necrotic cells, yet in addition by direct emission and exocytosis. On account of disease, some portion of the circling cfDNA compares to the DNA discharged by malignancy cells. This ctDNA conveys tumor explicit atomic modifications, for example, changes, translocations, loss of heterozygosity, duplicate number adjustments, and methylations [23]. Disengagement of ctDNA is practical for a few tumor restrictions, including OvC. In addition, it very well may be improved after section size choice. One of the primary focal points of ctDNA is that it should preferable reflecting tumor heterogeneity over tissue biopsies. Concerning OvC, cfDNA, and ctDNA investigations have been generally depicted during the most recent decade. Their potential applications go from screening to the expectation of reaction to foundational treatments and checking of subclinical illness. Translational and clinical examinations are in progress to affirm the clinical legitimacy and utility of these biomarkers. Despite the fact that most high evaluation OvCs are typically delicate to platinum-based chemotherapy in a first-line setting, a quarter are at first safe and all backsliding patients at some point or another become safe. Shockingly, no natural substitute marker of platinum-obstruction has been tentatively approved and can be utilized in clinical routine practice. Circling biomarkers could, accordingly, be of enthusiasm for this setting.

Conclusion: Distributions identified with fluid biopsies and OvC have exponentially expanded since 2010. The capacity of such biopsies to be rehashed at a few time focuses and late innovative advances permitting early recognition of OvC-related anomalies will probably prompt their utilization in clinical practice in the following scarcely any years, quite for treatment checking, identification of insignificant remaining sickness, and early analysis of backslide utilizing ctDNA and CTCs (Table 3). Expansion to different settings, such as screening and early determination, will require further investigation. All things considered, their clinical legitimacy and utility should initially be demonstrated, streamlined and expenses ought to be decreased before they might be generally suggested and routinely accessible. Aftereffects of imminent partner contemplate and randomized preliminaries utilizing fluid biopsies for the agnostic reasons for existing are consequently justified.